Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
UNCY
#3731
Unicycive Therapeutics, Inc. Common Stock
7.090
0
USD
+2.16%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+2.16%
Monthly Change
+1.72%
6 month change
+8.91%
Year Change
+8.91%
Previous Close
6.940
0
Open
6.960
0
Bid
Ask
Low
6.885
0
High
7.135
0
Volume
115
Markets
US Stock Market
Healthcare
UNCY
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
1.5 M
1.52 M
3.48 M
11.97 M
25.24 M
—
Valuation ratios
Enterprise value
14.47 M
7.16 M
45.68 M
68.93 M
116.42 M
278.93 M
Price to earnings ratio
-2.4
-0.42
-0.69
-1.42
-3.46
-138.18
Price to sales ratio
1 265.9
7.92
32.2
—
—
—
Price to cash flow ratio
-4.17
-0.48
-1.19
-1.86
-2.93
-7.62
Price to book ratio
1.46
-16.16
-0.4
7.16
3.04
6.18
Enterprise value to EBITDA ratio
-1.88
-0.41
-2.2
-2.15
—
—
Profitability ratios
Return on assets %
-0.53
-6.41
-2.15
-1.16
-0.54
-0.61
Return on equity %
-0.61
38.75
8.02
-4.94
-0.88
-0.99
Return on invested capital %
-2 325.65
-5 831.7
-604.02
-573.17
-630.94
—
Gross margin %
100
100
100
—
—
—
Operating margin %
-47.25 K
-1 898.21
-3 077.63
—
—
—
EBITDA margin %
-40.51 K
-1 853.21
-3 076.3
—
—
—
Net margin %
-52.72 K
-1 898.84
-4 525.04
—
—
—
Liquidity ratios
Quick ratio
—
0.14
—
—
—
—
Current ratio
8.75
0.81
0.76
1.28
2.59
10.23
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.09
0.08
0
—
—
Solvency ratios
Debt to assets ratio
0.01
—
—
—
—
—
Debt to equity ratio
0.01
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
—
—
—
Long term debt to total equity ratio
0
—
—
—
—
—
Per share metrics
Operating cash flow per share
-4.94
-10.39
-7.45
-4.27
-1.97
-2.24
EBIT per share
-7.67
-11.99
-8.47
-4.79
—
—
EBITDA per share
-6.59
-11.7
-8.46
-4.79
—
—
Total debt per share
0.13
—
—
—
—
—
Cash per share
14.2
0.3
14.3
3.9
2.6
8.37
Net current asset value per share
15.77
1.76
5.46
4.62
3.08
10.47
Tangible book value per share
14.12
-0.31
-21.93
1.11
1.9
6.22
Working capital per share
13.97
-0.43
-1.69
1.02
1.89
6.11
Book value per share
14.12
-0.31
-21.93
1.11
1.9
6.22
News
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
FDA sets June 27 review date for Unicycive’s kidney drug
Unicycive stock rises after FDA accepts OLC drug application resubmission
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission
Unicycive resubmits NDA for kidney disease treatment to FDA
Piper Sandler highlights commercial biotech names to own in 2026
Unicycive stock price target lowered to $63 by Lucid Capital Markets
Unicycive to resubmit FDA application for kidney drug by year-end
Unicycive Therapeutics faces securities class action lawsuit over public statements
Unicycive receives U.S. patent for chronic kidney disease treatment
Unicycive Therapeutics: Manageable CMC Speed Bump - Pill Burden Edge Intact, Buying (UNCY)
Unicycive regains Nasdaq compliance after reverse stock split